德国勃林格殷格翰的思力华怎么样？

(Repimat) is actually a spray form of tiotropium bromide, used for the long-term maintenance treatment of patients with chronic obstructive pulmonary disease (COPD, referred to as COPD, including chronic bronchitis and emphysema) to relieve symptoms. Tiotropium is also available in a dry powder inhalation form, both manufactured by Boehringer Ingelheim, Germany. When Respimat first came out, it was considered unsafe by some scholars. Later research (TIOSPIR research) proved that Respimat is as safe as Spirax. The TIOSPIR study is a multi-center, randomized controlled trial with a large sample size and the highest level of evidence, so the conclusions drawn are very reliable.

Germany's Boehringer Ingelheim is the world's largest private pharmaceutical company, with 5 R&D centers around the world and more than 8,100 R&D and medical department employees. Spiriva developed by it is a long-term effective anticholinergic agent. Patients with chronic obstructive pulmonary disease have strong relaxation of the lost nerves. Spiriva can effectively prevent the relaxation of lost nerves in patients with chronic obstructive pulmonary disease, allowing the nerves to contract smoothly. Taking Seretide and Seriva together can make the patient's bronchial expansion and contraction more stable, inhibit the airflow obstruction caused by inflammation from multiple aspects, improve the patient's hypoxia symptoms, inhibit the incidence of complications, and have a good effect on the recovery of the patient's health.

In a study conducted in China, the blood gas indicators and serum inflammatory factor levels of the observation group treated with combined medication were better than those of the control group (P<0.05). The patient satisfaction of the observation group was significantly higher than that of the control group (P<0.05). The asthma symptom score was significantly improved, and the COPD symptom score was significantly reduced. The improvement of the observation group was significantly better than that of the control group (P<0.05).

Studies have shown that the combination of Seretide and Seretide is very effective in the treatment of chronic obstructive pulmonary disease. After treatment, the relevant indicators of the patients have improved significantly, and there are no adverse reactions during the treatment period, which is highly safe. The combination of the two groups of drugs is an effective method for the treatment of chronic obstructive pulmonary disease.

Recommended hot articles: /newsDetail/92359.html